Sironax is a clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases. Founded in 2017, the company has built a diverse pipeline of programs by targeting contributors of aging, degeneration, metabolic dysfunction, and inflammation. Sironax is conducting clinical studies with SARM1 inhibitor SIR2501, NAMPT activator SIR4156, and RIPK1 inhibitor SIR9900, in addition to ongoing preclinical research. The company was named to the 2025 Endpoints 11 list of the most promising biotech startups. For more information, visit sironax.com.
| Website | https://www.sironax.com/ |
| Revenue | $60.8 million |
| Employees | 60 (20 on RocketReach) |
| Founded | 2017 |
| Address | 100 5th Avenue 4th Floor, Waltham, Massachusetts 02451, US |
| Industry | Biotechnology |
| Keywords | Biotechnology, Degenerative Diseases, Clinical Stage, Age Related Diseases, Novel Treatments, Drug Discovery, Therapeutic Development, Pharmaceutical Research, Biopharmaceutical, Pipeline Development, Global Health, Patient Care, Health Technology, Medical Research, Clinical Trials, Drug Development, Biotechnology Research, Pharmaceutical |
| Competitors | Amgen, Novartis, Biogen, CRISPR Therapeutics, Cellectis, Zymeworks Inc., Aldevron, Caribou Biosciences, Intellia Therapeutics, Inc., Editas Medicine +42 more (view full list) |
Looking for a particular Sironax employee's phone or email?
The Sironax annual revenue was $60.8 million in 2026.
Robin Sutherland is the Vice President, Global Head of HR, US Operations and Medical Affairs of Sironax.
20 people are employed at Sironax.
Sironax is based in Waltham, Massachusetts.